Bristol Myers Squibb (NYSE: BMY) is committing up to USD 950 million in near-term structured payments to access a portfolio of 13 early-stage programs from Hengrui Pharma (SSE: 600276; HKEX: 01276), in one of the largest deals struck between a major Western pharma company and a Chinese drug developer. The global strategic collaboration and license agreements span oncology, hematology, and immunology, with a total potential value of up to approximately USD 15.2 billion including milestones and option exercises. The structure gives BMS ex-China rights to Hengrui-originated assets while embedding BMS's immunology portfolio into Hengrui's discovery infrastructure for the Chinese market.
Under the terms, BMS will pay Hengrui USD 600 million at closing, followed by a USD 175 million first anniversary payment and a contingent USD 175 million second anniversary payment in 2028, totaling USD 950 million in structured near-term payments. Beyond that, the USD 15.2 billion ceiling reflects development, regulatory, and commercial milestones across all 13 programs, plus option exercise payments tied to five jointly discovered programs. Hengrui is also eligible to receive tiered royalties on net sales outside its territory; specific royalty rates were not disclosed. The deal is subject to Hart-Scott-Rodino antitrust review and is expected to close in Q3 2026.
Deal context
The 13 programs are divided into three categories: four oncology and hematology assets originated by Hengrui, four immunology assets contributed by BMS, and five programs to be jointly discovered and developed using Hengrui's platform technologies. All programs are described as early-stage, and Hengrui will be responsible for early clinical development to establish proof of concept across the portfolio.
Among the Hengrui-originated assets, the press release does not name individual molecules. Based on Hengrui's disclosed pipeline, the oncology and hematology programs are consistent with the company's established small molecule and antibody-drug conjugate capabilities. The five jointly discovered programs represent the most forward-looking element of the arrangement: rather than licensing existing molecules, BMS is gaining access to Hengrui's discovery engine across what the company describes as several innovative modalities, with both parties co-developing resulting candidates.
The geographic rights structure reflects the deal's bilateral design. BMS obtains exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong SAR, and Macau SAR. Hengrui, in turn, obtains exclusive rights to BMS-originated assets within that same territory, with BMS retaining rights for the rest of the world. Hengrui also retains the option to co-develop select assets and to conduct certain commercialization activities globally alongside BMS.
The deal context
BMS has been actively rebuilding its early-stage pipeline through external partnerships, and a deal of this scale — structured across three therapeutic areas with both licensing and discovery components — reflects a deliberate effort to accelerate early clinical learning without bearing the full cost of internal discovery. By embedding Hengrui's discovery engine into five jointly developed programs, BMS is effectively acquiring ongoing access to a high-throughput, multi-modal Chinese R&D capability at a fraction of the cost of replicating it internally.